Regeneron Pharmaceuticals
REGN
578 hedge funds and large institutions have $27.9B invested in Regeneron Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 73 funds opening new positions, 226 increasing their positions, 194 reducing their positions, and 60 closing their positions.
42% more funds holding in top 10
Funds holding in top 10: 12 → 17 (+5)
22% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 60
16% more repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 194
6% more capital invested
Capital invested by funds: $26.3B → $27.9B (+$1.51B)
0% more funds holding
Funds holding: 576 → 578 (+2)
0.29% less ownership
Funds ownership: 69.35% → 69.06% (-0.29%)
15% less call options, than puts
Call options by funds: $728M | Put options by funds: $852M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.21B |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$234M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$180M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$173M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$166M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$445M |
| 2 |
Jennison Associates
New York
|
-$429M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$250M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$104M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$87.8M |
REGN Hedge Fund Activity: Q1 2017 in Review
578 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2017, worth a combined $27.9B — up 5.7% from $26.3B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new REGN positions and 60 closed out — a net gain of 13 holders — while 226 added to existing stakes and 194 trimmed.
The largest buyer was BlackRock, adding an estimated $2.21B. The largest seller was Fidelity Investments, cutting an estimated $445M.
- 578 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2017, up from 576 in Q4 2016.
- Funds reported $27.9B of Regeneron Pharmaceuticals stock for Q1 2017, up 5.7% quarter-over-quarter.
- 73 funds opened new Regeneron Pharmaceuticals positions in Q1 2017 and 60 closed out, a net change of +13 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $2.21B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2017 was Fidelity Investments, an estimated $445M sold.
Based on aggregated 13F filings for Q1 2017.